Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice

Dexing Zeng, Yunjun Guo, Alexander G. White, Zhengxin Cai, Jalpa Modi, Riccardo Ferdani, Carolyn J. Anderson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Epidermal growth-factor receptor (EGFR) is overexpressed in a wide variety of solid tumors and has served as a well-characterized target for cancer imaging and therapy. Cetuximab was the first mAb targeting EGFR approved by the FDA for the treatment of metastatic colorectal and head and neck cancers. Previous studies showed that 64Cu (T1/2 = 12.7 h; β+ (17.4%)) labeled DOTA-cetuximab showed promise for PET imaging of EGFR-positive tumors; however the in vivo stability of this compound has been questioned. In this study, two recently developed cross-bridged macrocyclic chelators (CB-TE1A1P and CB-TE1K1P) were conjugated to cetuximab using standard NHS coupling procedures and/or strain-promoted azide-alkyne cycloaddition (SPAAC) methodologies. The radiolabeling and in vitro/vivo evaluation of the resulting cetuximab conjugates were compared. Improved Cu-64 labeling efficiency and high specific activity (684 kBq/μg, decay corrected to the end of bombardment) were obtained with the CB-TE1K1P-PEG4-click-cetuximab conjugate. Saturation binding assays indicated that the prepared cetuximab conjugates had comparable affinity (1.32-2.00 nM) in the HCT116 human colorectal tumor cell membranes. In the subsequent in vivo evaluation, 64Cu-CB-TE1K1P-PEG4-click-cetuximab demonstrated more rapid renal clearance with a higher tumor/nontumor ratio than other 64Cu-labeled cetuximab conjugates, and it shows the greatest promise for imaging and therapy of EGFR-positive tumors.

Original languageEnglish (US)
Pages (from-to)3980-3987
Number of pages8
JournalMolecular Pharmaceutics
Volume11
Issue number11
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Chelating Agents
Epidermal Growth Factor Receptor
Copper
Colorectal Neoplasms
Neoplasms
Alkynes
Azides
Cetuximab
Cycloaddition Reaction
Head and Neck Neoplasms
Cell Membrane
Kidney
Therapeutics

Keywords

  • Cetuximab
  • Copper-64
  • Cross-bridged chelator
  • Epidermal growth-factor receptor
  • Metal-free click chemistry
  • PET imaging

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice. / Zeng, Dexing; Guo, Yunjun; White, Alexander G.; Cai, Zhengxin; Modi, Jalpa; Ferdani, Riccardo; Anderson, Carolyn J.

In: Molecular Pharmaceutics, Vol. 11, No. 11, 01.01.2014, p. 3980-3987.

Research output: Contribution to journalArticle

Zeng, Dexing ; Guo, Yunjun ; White, Alexander G. ; Cai, Zhengxin ; Modi, Jalpa ; Ferdani, Riccardo ; Anderson, Carolyn J. / Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice. In: Molecular Pharmaceutics. 2014 ; Vol. 11, No. 11. pp. 3980-3987.
@article{7f6a3e5c3f114bf79df76274ad29d869,
title = "Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice",
abstract = "Epidermal growth-factor receptor (EGFR) is overexpressed in a wide variety of solid tumors and has served as a well-characterized target for cancer imaging and therapy. Cetuximab was the first mAb targeting EGFR approved by the FDA for the treatment of metastatic colorectal and head and neck cancers. Previous studies showed that 64Cu (T1/2 = 12.7 h; β+ (17.4{\%})) labeled DOTA-cetuximab showed promise for PET imaging of EGFR-positive tumors; however the in vivo stability of this compound has been questioned. In this study, two recently developed cross-bridged macrocyclic chelators (CB-TE1A1P and CB-TE1K1P) were conjugated to cetuximab using standard NHS coupling procedures and/or strain-promoted azide-alkyne cycloaddition (SPAAC) methodologies. The radiolabeling and in vitro/vivo evaluation of the resulting cetuximab conjugates were compared. Improved Cu-64 labeling efficiency and high specific activity (684 kBq/μg, decay corrected to the end of bombardment) were obtained with the CB-TE1K1P-PEG4-click-cetuximab conjugate. Saturation binding assays indicated that the prepared cetuximab conjugates had comparable affinity (1.32-2.00 nM) in the HCT116 human colorectal tumor cell membranes. In the subsequent in vivo evaluation, 64Cu-CB-TE1K1P-PEG4-click-cetuximab demonstrated more rapid renal clearance with a higher tumor/nontumor ratio than other 64Cu-labeled cetuximab conjugates, and it shows the greatest promise for imaging and therapy of EGFR-positive tumors.",
keywords = "Cetuximab, Copper-64, Cross-bridged chelator, Epidermal growth-factor receptor, Metal-free click chemistry, PET imaging",
author = "Dexing Zeng and Yunjun Guo and White, {Alexander G.} and Zhengxin Cai and Jalpa Modi and Riccardo Ferdani and Anderson, {Carolyn J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1021/mp500004m",
language = "English (US)",
volume = "11",
pages = "3980--3987",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET Imaging of EGFR in colorectal tumor-bearing mice

AU - Zeng, Dexing

AU - Guo, Yunjun

AU - White, Alexander G.

AU - Cai, Zhengxin

AU - Modi, Jalpa

AU - Ferdani, Riccardo

AU - Anderson, Carolyn J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Epidermal growth-factor receptor (EGFR) is overexpressed in a wide variety of solid tumors and has served as a well-characterized target for cancer imaging and therapy. Cetuximab was the first mAb targeting EGFR approved by the FDA for the treatment of metastatic colorectal and head and neck cancers. Previous studies showed that 64Cu (T1/2 = 12.7 h; β+ (17.4%)) labeled DOTA-cetuximab showed promise for PET imaging of EGFR-positive tumors; however the in vivo stability of this compound has been questioned. In this study, two recently developed cross-bridged macrocyclic chelators (CB-TE1A1P and CB-TE1K1P) were conjugated to cetuximab using standard NHS coupling procedures and/or strain-promoted azide-alkyne cycloaddition (SPAAC) methodologies. The radiolabeling and in vitro/vivo evaluation of the resulting cetuximab conjugates were compared. Improved Cu-64 labeling efficiency and high specific activity (684 kBq/μg, decay corrected to the end of bombardment) were obtained with the CB-TE1K1P-PEG4-click-cetuximab conjugate. Saturation binding assays indicated that the prepared cetuximab conjugates had comparable affinity (1.32-2.00 nM) in the HCT116 human colorectal tumor cell membranes. In the subsequent in vivo evaluation, 64Cu-CB-TE1K1P-PEG4-click-cetuximab demonstrated more rapid renal clearance with a higher tumor/nontumor ratio than other 64Cu-labeled cetuximab conjugates, and it shows the greatest promise for imaging and therapy of EGFR-positive tumors.

AB - Epidermal growth-factor receptor (EGFR) is overexpressed in a wide variety of solid tumors and has served as a well-characterized target for cancer imaging and therapy. Cetuximab was the first mAb targeting EGFR approved by the FDA for the treatment of metastatic colorectal and head and neck cancers. Previous studies showed that 64Cu (T1/2 = 12.7 h; β+ (17.4%)) labeled DOTA-cetuximab showed promise for PET imaging of EGFR-positive tumors; however the in vivo stability of this compound has been questioned. In this study, two recently developed cross-bridged macrocyclic chelators (CB-TE1A1P and CB-TE1K1P) were conjugated to cetuximab using standard NHS coupling procedures and/or strain-promoted azide-alkyne cycloaddition (SPAAC) methodologies. The radiolabeling and in vitro/vivo evaluation of the resulting cetuximab conjugates were compared. Improved Cu-64 labeling efficiency and high specific activity (684 kBq/μg, decay corrected to the end of bombardment) were obtained with the CB-TE1K1P-PEG4-click-cetuximab conjugate. Saturation binding assays indicated that the prepared cetuximab conjugates had comparable affinity (1.32-2.00 nM) in the HCT116 human colorectal tumor cell membranes. In the subsequent in vivo evaluation, 64Cu-CB-TE1K1P-PEG4-click-cetuximab demonstrated more rapid renal clearance with a higher tumor/nontumor ratio than other 64Cu-labeled cetuximab conjugates, and it shows the greatest promise for imaging and therapy of EGFR-positive tumors.

KW - Cetuximab

KW - Copper-64

KW - Cross-bridged chelator

KW - Epidermal growth-factor receptor

KW - Metal-free click chemistry

KW - PET imaging

UR - http://www.scopus.com/inward/record.url?scp=84965184789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965184789&partnerID=8YFLogxK

U2 - 10.1021/mp500004m

DO - 10.1021/mp500004m

M3 - Article

VL - 11

SP - 3980

EP - 3987

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -